TALON Phase IIIb Study: 32-Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age-Related Macular Degeneration.
Saved in:
| Title: | TALON Phase IIIb Study: 32-Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age-Related Macular Degeneration. |
|---|---|
| Authors: | Regillo C; Retina Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania. Electronic address: cregillo@gmail.com., Kaiser PK; Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio., Kertes PJ; The John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Gillies M; Clinical Ophthalmology and Eye Health, Sydney Eye Hospital, The University of Sydney, Sydney, Australia., Maio-Twofoot T; Novartis Pharma A.G., Basel, Switzerland., D'Souza D; SepulBio, a Thea Business Unit, Waltham, Massachusetts., Guenther S; Novartis Pharma A.G., Basel, Switzerland., Lawrence D; Novartis Pharma A.G., Basel, Switzerland., Holz FG; Department of Ophthalmology, University of Bonn, Bonn, Germany. |
| Source: | Ophthalmology. Retina [Ophthalmol Retina] 2025 Dec; Vol. 9 (12), pp. 1175-1186. Date of Electronic Publication: 2025 Jun 02. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study |
| Journal Info: | Publisher: Published by Elsevier Inc. on behalf of American Academy of Ophthalmology Country of Publication: United States NLM ID: 101695048 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2468-6530 (Electronic) Linking ISSN: 24686530 NLM ISO Abbreviation: Ophthalmol Retina Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
